Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Using gemcitabine and nab-paclitaxel, the investigators hope to establish the differential
ability of local and cytologically positive disease to respond to this regimen, and in
particular, the frequency of cytologic conversion from positive to negative in such patients.
The investigators also can begin to assess the value of maximum local therapy, including
surgery, in patients who cytologically convert from positive to negative.